Glenmark Pharmaceuticals Limited · NSE:GLENMARK
Glenmark Pharmaceuticals — Q2 FY25 Earnings Presentation
18 slides from Glenmark Pharmaceuticals's earnings presentation, Nov 14, 2024
Slide 1: Exchange filing cover letter for Investor Presentation
November 14, 2024 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 532296
Slide 2: Investor Presentation: Q2 FY25
Investor Presentation: Q2 FY25 14 November 2024
Slide 3: Disclaimer
Disclaimer This document has been prepared by Glenmark Pharmaceuticals Ltd. and the information, statements and analysis made in this document describing the Company’s or its affiliates’ objectives, projections and estimates are forward looking statements. Forward-looking statements are all statemen
Slide 4: Q2 FY25 Summary
Q2 FY25 Summary “This quarter, we have maintained a strong growth trajectory, driven by robust performances in the India Consolidated • Q2 Consolidated Revenue of Rs. 34,338 Mn and Europe markets. Our flagship respiratory brand, Revenue • YoY growth of 7.1% RYALTRIS®, continues to perform well acros
Slide 5: Consolidated Revenue – Q2 FY25
Consolidated Revenue – Q2 FY25 Second Quarter ended September 30 First Quarter ended June 30 Rs Mn FY 2024-25 FY 2023-24 YoY Growth (%) FY 2024-25 QoQ Growth (%) India 12,817 11,252 13.9% 11,962 7.1% North America 7,405 7,498 -1.2% 7,808 -5.2% Europe 6,874 5,997 14.6% 6,957 -1.2% Rest of the World1
Slide 6: Revenue Contribution – Q2 FY25
Revenue Contribution – Q2 FY25 0% 0% 1% 18% 20% 23% 35% 37% 37% Q2 Q1 Q2 FY24 21% FY25 FY25 19% 20% 23% 24% 22% India Europe Other Revenue North America ROW 5 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 7: P&L Highlights
P&L Highlights Rs. Mn Q2 FY25 Q2 FY24 %YoY Q1 FY25 %QoQ 6M FY25 6M FY24 %YoY Revenues from Operations 34,338 32,074 7.1% 32,442 5.8% 66,780 62,434 7.0% Gross Margin 23,637 20,096 21,341 44,978 38,579 Gross Margin (%) 68.8% 62.7% 65.8% 67.4% 61.8% EBITDA 6,019 4,623 30.2% 5,882 2.3% 11,901 8,996 32.3
Slide 8: India
Q2 FY25 37.3 India % Revenue (Rs. million) YoY: 13.9% Sustained outperformance – Glenmark now ranked 13th QoQ: 7.1% ~1.5x of IPM growth in IPM 12,817 11,962 11,252 Key Highlights Glenmark continues to significantly outperform the IPM in terms of YoY growth - 12.7% in Q2 FY25 and 13.1% as per MAT S
Slide 9: North America
Q2 FY25 37.3 North America % Revenue (Rs. million) YoY: -1.2% 8 injectable products are Plan to launch 3-4 products QoQ: -5.2% now commercial in Q3 FY25 7,405 7,498 7,808 Key Highlights Filed 1 ANDA application in Q2 FY25; plan to file 2 ANDAs in Q3 FY25 Products launched in Q2 FY25 Q2 FY25 Q2 F
Slide 10: Europe
Q2 FY25 37.3 Europe % Revenue (Rs. million) YoY: 14.6% Sustained growth in the QoQ: -1.2% Continued outperformance branded Respiratory in the CEE regional markets business across markets 6,874 6,957 5,997 Key Highlights Q2 FY25 Q2 FY24 Q1 FY25 All the key countries recorded healthy growth Brande
Slide 11: Rest Of the World (ROW)
Q2 FY25 37.3 Rest Of the World (ROW)1 % Revenue (Rs. million) YoY: -4.1% RYALTRIS® continues to Aiming for high single-digit QoQ: 23.3% scale up and increase YoY growth in FY25 7,041 7,339 market share 5,708 Key Highlights Russia: Recorded secondary sales growth of 16% and 19% in value as per IQVI
Slide 12: Creating Global Brands – RYALTRIS
Creating Global Brands – RYALTRIS® As of September 2024, marketing applications for RYALTRIS® have been submitted in more than 90 countries across the world and the product has been commercialized in 41 markets. Further, it has received approval and will be launched in 10-11 additional markets ove
Slide 13: Creating Global Brands – ENVAFOLIMAB & WINLEVI
Creating Global Brands – ENVAFOLIMAB & WINLEVI® ENVAFOLIMAB The Company announced the signing of a license agreement with Jiangsu Alphamab Biopharmaceuticals Co., Ltd (Jiangsu Alphamab) and 3D Medicines (Beijing) Co., Ltd. (3DMed) for Envafolimab for India, Asia Pacific, Middle East and Africa, Ru
Slide 14: Ichnos Glenmark Innovation
ICHNOS GLENMARK INNOVATION TREAT: Trispecific Engagement by Antibodies based on the T cell receptor BEAT: Bispecific Engagement by Antibodies based on the T cell receptor 13 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 15: Ichnos Glenmark Innovation: Multiple Myeloma overview and ISB 2001
ICHNOS GLENMARK INNOVATION MULTIPLE MYELOMA (MM) OVERVIEW • Remains a devastating and often fatal disease, with no current cure available. Despite advancements in treatment, many patients continue to face poor outcomes, especially those with relapsed or refractory (r/r) disease. • Market projected t
Slide 16: ISB 2001 data presentation at ASH2024
ICHNOS GLENMARK INNOVATION ISB 2001 DATA PRESENTATION AT ASH2024 • IGI to present first-time data from its Phase 1 study of ISB 2001 in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting • The abstract features data as of July 2024, including: o An overall response
Slide 17: Key objectives for FY25
Key objectives for FY25 1 Consolidated revenue: Rs. 1,35,000 – 1,40,000 million 2 R&D investment: 7-7.25% of total sales 3 EBITDA margin: ~19% 4 Consolidated CAPEX: Rs. 7,000 million 5 Target double-digit PAT margin 16 ©2023 Glenmark Pharmaceuticals Ltd. All Rights Reserved
Slide 18: Thank You
G Glenmark Thank You
Glenmark Pharmaceuticals — Q2 FY25 Earnings Presentation on 6ix